BBIO - BridgeBio rises after late-stage muscular dystrophy trial success
2025-10-27 13:09:28 ET
More on BridgeBio Pharma
- BridgeBio Pharma, Inc. (BBIO) Discusses Positive FORTIFY Phase III Interim Results in Limb-Girdle Muscular Dystrophy Type 2I/R9 Transcript
- BridgeBio Pharma, Inc. (BBIO) Discusses Positive FORTIFY Phase III Interim Results in Limb-Girdle Muscular Dystrophy Type 2I/R9 - Slideshow
- BridgeBio Pharma, Inc. (BBIO) Presents at HFSA 2025 - Slideshow
- SA Asks: What's the most attractive biotech stock right now?
- Pfizer, Alnylam earn BridgeBio ire over sales tactics for amyloidosis drugs: Bloomberg